24 results
8-K
EX-99.4
ELTX
Elicio Therapeutics Inc.
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
to support the initiation of clinical trials;
regulators or IRBs or Independent Ethics Committees (IECs) may not authorize Elicio or its … that Elicio consult with relevant review and ethics committees, IRBs, and the FDA. The foregoing may also impact the integrity of Elicio’s study data
8-K
EX-99.3
ELTX
Elicio Therapeutics Inc.
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics
424B3
ELTX
Elicio Therapeutics Inc.
28 Apr 23
Prospectus supplement
4:07pm
and Ethics
Corporate Governance Guidelines
Hedging Policy
MATTERS BEING SUBMITTED TO A VOTE OF ANGION’S STOCKHOLDERS
PROPOSAL NO. 1 (THE STOCK ISSUANCE … Participation
Corporate Governance Guidelines
Code of Business Conduct and Ethics
ANGION EXECUTIVE AND DIRECTOR COMPENSATION
Executive Officer Compensation
S-4/A
EX-10.26
ihou325mut0w j6
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
S-4/A
fu0msne
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
DEF 14A
rrvnskd vq6emsp39
27 Apr 22
Definitive proxy
4:04pm
10-Q
27omic7k74 7e1
17 May 21
Quarterly report
6:03am
10-K
vmi3xqi 8qd9
30 Mar 21
Annual report
5:00pm
424B4
8ikhqrzqf1lds38 33du
5 Feb 21
Prospectus supplement with pricing info
5:12pm